검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Live (Measles-Mumps-Rubella Vaccine, Measles-Mumps-Rubella Vaccine (Live)) Merck Sharp & Dohme LLC·HIV Infections 0% |
|---|---|
Overview Program | Measles-Mumps-Rubella Vaccine (Live) |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targets with TNBC-associated proteins, highlighting enrichment in PI3K/AKT/mTOR, HIF-1, AGE-RAGE, calcium signaling, and microRNA-related pathway |
MoA Biomarker | biomarker-guided patient stratification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation.. Antimicrobial resistance demands intensive research on new nonantibiotics and drug repurposing to expand the arsenal of antimicrobial agents. The present work analysed the combination of diclofenac (DFNAC) and cannabidiol (CBD) and evaluated its potentiation and its biocompatibi… |
Clinical Primary efficacy | 0% |
Clinical ORR | 0% |
Clinical PFS | 10 |
Clinical OS | 5 |
Clinical Result source | ClinicalTrials.gov NCT03371381 |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Live (Measles-Mumps-Rubella Vaccine, Measles-Mumps-Rubella Vaccine (Live)) Merck Sharp & Dohme LLC·HIV Infections 0% |
|---|---|
Overview Program | Measles-Mumps-Rubella Vaccine (Live) |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ANTIBODY |
Overview Target | HIV Infections |
Overview Indication | HIV Infections; Hepatitis B |
Overview Phase | PRECLINICAL |
Overview Status | ACTIVE |
MoA Mechanism | targets with TNBC-associated proteins, highlighting enrichment in PI3K/AKT/mTOR, HIF-1, AGE-RAGE, calcium signaling, and microRNA-related pathway |
MoA Biomarker | biomarker-guided patient stratification |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Combining Diclofenac and Cannabidiol to Enhance the Antibacterial Capacity of Nonantibiotic Drugs Through Potentiation.. Antimicrobial resistance demands intensive research on new nonantibiotics and drug repurposing to expand the arsenal of antimicrobial agents. The present work analysed the combination of diclofenac (DFNAC) and cannabidiol (CBD) and evaluated its potentiation and its biocompatibi… |
Clinical Primary efficacy | 0% |
Clinical ORR | 0% |
Clinical PFS | 10 |
Clinical OS | 5 |
Clinical Result source | ClinicalTrials.gov NCT03371381 |
Clinical Data Tier / Score | A · 30 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교